Key clinical point: CT-P10, a rituximab biosimilar, was equivalent in efficacy to rituximab and was well tolerated in the treatment of low–tumor-burden follicular lymphoma.
Major finding: Overall response after 7 months of treatment was seen in 83% of patients randomized to CT-P10 and 81% of patients randomized to rituximab.
Study details: Analysis of 258 patients randomized to CT-P10 or rituximab in a phase 3, double-blind, parallel-group trial.
Disclosures: The trial was sponsored by Celltrion and three coauthors of the study were employees of the company. Other study coauthors reported disclosures related to Celltrion, Novartis, Roche, AbbVie, Celgene, and Takeda, among other companies.
Ogura M et al. Lancet Haematol. 2018 Nov;5(11):e543-53